IL173965A - Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell - Google Patents

Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell

Info

Publication number
IL173965A
IL173965A IL173965A IL17396506A IL173965A IL 173965 A IL173965 A IL 173965A IL 173965 A IL173965 A IL 173965A IL 17396506 A IL17396506 A IL 17396506A IL 173965 A IL173965 A IL 173965A
Authority
IL
Israel
Prior art keywords
vitro
activating
cell
pharmaceutical compositions
peptide compounds
Prior art date
Application number
IL173965A
Other languages
English (en)
Hebrew (he)
Other versions
IL173965A0 (en
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL173965(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of IL173965A0 publication Critical patent/IL173965A0/en
Publication of IL173965A publication Critical patent/IL173965A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
IL173965A 2003-08-28 2006-02-27 Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell IL173965A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (2)

Publication Number Publication Date
IL173965A0 IL173965A0 (en) 2006-07-05
IL173965A true IL173965A (en) 2015-10-29

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173965A IL173965A (en) 2003-08-28 2006-02-27 Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell

Country Status (32)

Country Link
US (1) US7576056B2 (cg-RX-API-DMAC7.html)
EP (1) EP1675606B1 (cg-RX-API-DMAC7.html)
JP (1) JP4848277B2 (cg-RX-API-DMAC7.html)
KR (2) KR20120078742A (cg-RX-API-DMAC7.html)
CN (2) CN1871022B (cg-RX-API-DMAC7.html)
AR (1) AR045530A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004270656B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414008B8 (cg-RX-API-DMAC7.html)
CA (1) CA2537421C (cg-RX-API-DMAC7.html)
CY (1) CY1118965T1 (cg-RX-API-DMAC7.html)
DK (1) DK1675606T3 (cg-RX-API-DMAC7.html)
EA (1) EA009286B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP066396A (cg-RX-API-DMAC7.html)
ES (1) ES2626107T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170810T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032370T2 (cg-RX-API-DMAC7.html)
IL (1) IL173965A (cg-RX-API-DMAC7.html)
IS (1) IS8300A (cg-RX-API-DMAC7.html)
LT (1) LT1675606T (cg-RX-API-DMAC7.html)
ME (1) ME00313B (cg-RX-API-DMAC7.html)
MX (1) MXPA06002292A (cg-RX-API-DMAC7.html)
NO (1) NO344233B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ545455A (cg-RX-API-DMAC7.html)
PL (1) PL1675606T3 (cg-RX-API-DMAC7.html)
PT (1) PT1675606T (cg-RX-API-DMAC7.html)
RS (2) RS56387B1 (cg-RX-API-DMAC7.html)
SG (1) SG131110A1 (cg-RX-API-DMAC7.html)
SI (1) SI1675606T1 (cg-RX-API-DMAC7.html)
TW (1) TWI348375B (cg-RX-API-DMAC7.html)
UA (1) UA82710C2 (cg-RX-API-DMAC7.html)
WO (1) WO2005023834A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200602495B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
EP1124961B9 (en) 1998-10-23 2010-07-21 Kirin-Amgen Inc. Thrombopoietic compounds
NZ566812A (en) 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
EA009286B1 (ru) 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
MY151332A (en) * 2006-02-14 2014-05-15 Janssen Pharmaceutica Nv Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
CA2642389C (en) * 2006-02-14 2014-05-06 Janssen Pharmaceutica N.V. Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
KR20110015448A (ko) * 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 tpo 모방 펩티드
CN103635514B (zh) 2011-06-23 2016-01-20 株式会社岛津制作所 支链型两亲性嵌段聚合物、使用其的分子聚集体及药物输送系统
US12251424B2 (en) 2017-07-26 2025-03-18 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
US20200237872A1 (en) 2019-01-25 2020-07-30 Janssen Pharmaceutica Nv Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure
WO2020209920A2 (en) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas
EP3914272B1 (en) 2019-01-25 2024-03-06 Janssen Pharmaceutica NV Thrombopoietin mimetics for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
EP4408984A1 (en) 2021-10-01 2024-08-07 Janssen Pharmaceutica NV Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT644771E (pt) 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
EP0673387B1 (en) 1992-12-11 1999-09-22 University Of Florida Materials and methods for control of pests
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
WO1995021920A1 (en) 1994-02-14 1995-08-17 Zymogenetics, Inc. Hematopoietic protein and materials and methods for making it
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0723456A1 (en) 1994-02-14 1996-07-31 The University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
SG79882A1 (en) 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
DE69503849T2 (de) 1994-03-31 1999-04-01 Amgen Inc., Thousand Oaks, Calif. Zusammensetzungen und Verfahren zur Anregung des Wachstums und der Differenzierung von Megakaryozyten
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
CA2180021A1 (en) * 1994-11-04 1996-05-17 Yoichi Kawashima Novel 1,3-dialkylurea derivatives having a hydroxyl group
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
JP3763846B2 (ja) 1995-04-26 2006-04-05 協和醗酵工業株式会社 新規ポリペプチド
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EP1961760A3 (en) * 1995-06-07 2008-09-03 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
EP1223944B1 (en) 1999-09-24 2007-01-03 SmithKline Beecham Corporation Thrombopoietin mimetics
PL205949B1 (pl) * 2000-12-22 2010-06-30 Ipsen Mfg Ireland Ltd Sposób wytwarzania peptydu
WO2002078612A2 (en) 2001-04-02 2002-10-10 Euro-Celtique S.A. Thrombopoietin (tpo) synthebody for stimulation of platelet production
NZ566812A (en) * 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
EA009286B1 (ru) 2003-08-28 2007-12-28 Орто-Макнейл Фармасьютикал, Инк. Пептиды и соединения, которые связываются с рецептором

Also Published As

Publication number Publication date
TW200517103A (en) 2005-06-01
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
IL173965A0 (en) 2006-07-05
AU2004270656A1 (en) 2005-03-17
CN102241742B (zh) 2014-04-02
US20050137133A1 (en) 2005-06-23
ZA200602495B (en) 2007-06-27
EP1675606B1 (en) 2017-04-05
NO20061346L (no) 2006-05-22
CN1871022A (zh) 2006-11-29
JP2007504132A (ja) 2007-03-01
BRPI0414008B8 (pt) 2021-05-25
TWI348375B (en) 2011-09-11
UA82710C2 (uk) 2008-05-12
SG131110A1 (en) 2007-04-26
SI1675606T1 (sl) 2017-07-31
BRPI0414008B1 (pt) 2018-05-15
MEP48508A (en) 2011-02-10
NO344233B1 (no) 2019-10-14
AU2004270656B2 (en) 2011-03-10
WO2005023834A2 (en) 2005-03-17
PL1675606T3 (pl) 2017-08-31
EA009286B1 (ru) 2007-12-28
WO2005023834A3 (en) 2005-05-06
HUE032370T2 (en) 2017-09-28
HK1096873A1 (en) 2007-06-15
EP1675606A2 (en) 2006-07-05
LT1675606T (lt) 2017-11-10
NZ545455A (en) 2009-02-28
ECSP066396A (es) 2006-08-30
CY1118965T1 (el) 2018-01-10
MXPA06002292A (es) 2006-09-04
US7576056B2 (en) 2009-08-18
CA2537421C (en) 2011-09-27
CN1871022B (zh) 2011-07-06
CN102241742A (zh) 2011-11-16
PT1675606T (pt) 2017-05-22
EA200600477A1 (ru) 2007-02-27
RS56387B1 (sr) 2017-12-29
IS8300A (is) 2006-02-14
KR20070017942A (ko) 2007-02-13
KR20120078742A (ko) 2012-07-10
HRP20170810T1 (hr) 2017-08-11
RS20060141A (sr) 2008-08-07
CA2537421A1 (en) 2005-03-17
ES2626107T3 (es) 2017-07-24
BRPI0414008A (pt) 2006-10-24
ME00313B (me) 2011-05-10
JP4848277B2 (ja) 2011-12-28
AR045530A1 (es) 2005-11-02
KR101183875B1 (ko) 2012-09-27

Similar Documents

Publication Publication Date Title
IL173965A (en) Peptide compounds, pharmaceutical preparations containing them, uses and methods in vitro and ex vivo to activate a thrombopoietin receptor in the cell
IL174958A0 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
TWI319319B (en) New solid pharmaceutical formulations comprising telmisartan and preparation thereof
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
IL164376A0 (en) Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1469840A4 (en) PROLONGED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING CYCLOSPORINE
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
IL165383A0 (en) Pharmaceutical compositions with improved dissolution
EP1804823A4 (en) NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS
IL163894A (en) 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
IL184065A (en) Tetrahydroquinoline analogs, their use in the preparation of pharmaceuticals and pharmaceutical compositions containing them
IL184735A0 (en) Pharmaceutical formulations and methods of use
IL183974A (en) Derivatives of 5h - Benzocycloheptane Tetralin and Indane, medicinal preparations containing them, and their use in the preparation of medicines
EP1424994A4 (en) PREPARATION OF A SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION
EG24479A (en) Modified release pharmaceutical formulation
AU2003260803A8 (en) Sustained release pharmaceutical composition
ZA200705533B (en) Sustained release composition of protein drug
IL183044A0 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
ZA200606619B (en) Indazole derivatives and pharmaceutical compositions containing them
ZA200702938B (en) Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
EP1802346A4 (en) PHARMACEUTICAL COMPOSITION WITH EXTENDED RELEASE
EP1478353A4 (en) PHARMACEUTICAL COMPOSITION WITH DELAYED RELEASE
IL178067A0 (en) Pharmaceutical dosage forms and compositions
SI1673349T1 (sl) Derivati benzimidazola: priprava in farmacevtske uporabe

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed